公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2021 | Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study | Shao Z.; Tseng L.-M.; CHIUN-SHENG HUANG ; Pang D.; Yang Y.; Li W.; Liao N.; Geng C.; Zhang Q.; Xu B.; Liu D.; Kwong A.; et al (continued in the appendix) | Japanese journal of clinical oncology | 2 | 1 | |
2018 | Reply to 'the St Gallen international expert consensus on the primary therapy of early breast cancer 2017: Te point of view of an international panel of experts in radiation oncology' by Kirova et al. | Dubsky P.; Curigliano G.; Burstein H.J.; Winer E.P.; Gnant M.; Loibl S.; Colleoni M.; Regan M.M.; Piccart-Gebhart M.; Senn H.-J.; Thrlimann B.; Andr? F.; Baselga J.; Bergh J.; Bonnefoi H.; Brucker S.Y.; Cardoso F.; Carey L.; Ciruelos E.; Cuzick J.; Denkert C.; Di Leo A.; Ejlertsen B.; Francis P.; Galimberti V.; Garber J.; Gulluoglu B.; Goodwin P.; Harbeck N.; Hayes D.F.; CHIUN-SHENG HUANG ; Huober J.; Khaled H.; Jassem J.; Jiang Z.; Karlsson P.; Morrow M.; Orecchia R.; Osborne K.C.; Pagani O.; Partridge A.H.; Pritchard K.; Ro J.; Rutgers E.J.T.; Sedlmayer F.; Semiglazov V.; Shao Z.; Smith I.; Toi M.; Tutt A.; Viale G.; Watanabe T.; Whelan T.J.; Xu B.; on behalf of the Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 | Annals of Oncology | 2 | 3 | |
2019 | Trastuzumab emtansine for residual invasive HER2-positive breast cancer | Von Minckwitz G.; CHIUN-SHENG HUANG ; Mano M.S.; Loibl S.; Mamounas E.P.; Untch M.; Wolmark N.; Rastogi P.; Schneeweiss A.; Redondo A.; Fischer H.H.; Jacot W.; Conlin A.K.; Arce-Salinas C.; Wapnir I.L.; Jackisch C.; DiGiovanna M.P.; Fasching P.A.; Crown J.P.; W?lfing P.; Shao Z.; Caremoli E.R.; Wu H.; Lam L.H.; Tesarowski D.; Smitt M.; Douthwaite H.; Singel S.M.; Geyer C.E.; Jr. | New England Journal of Medicine | 1568 | 1351 |